• 1
    Dempster DW, Shane ES 2001 Bone quantification and dynamics of bone turnover by histomorphometric analysis In: BeckerKL (ed.) Principles and Practice of Endocrinology and Metabolism, 3rd ed. Lippincott Williams and Wilkins, Baltimore, MD, USA, pp. 541548.
  • 2
    de Vernejoul MC, Kuntz D, Miravet L, Goutallier D, Ryckewaert A 1981 Bone histomorphometric reproducibility in normal patients. Calcif Tissue Int 33:369374.
  • 3
    Chavassieux PM, Arlot ME, Meunier PJ 1985 Intersample variation in bone histomorphometry: Comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37:345350.
  • 4
    Podenphant J, Engel U 1987 Regional variations in histomorphometric bone dynamics from the skeleton of an osteoporotic woman. Calcif Tissue Int 40:184188.
  • 5
    Podenphant J, Riis BJ, Johansen JS, Leth A, Christiansen C 1988 Iliac crest biopsy in longitudinal therapeutic trials of osteoporosis. Bone Miner 5:7787.
  • 6
    Parisien MV, McMahon D, Pushparaj N, Dempster DW 1988 Trabecular architecture in iliac crest bone biopsies: Intra-individual variability in structural parameters and changes with age. Bone 9:289295.
  • 7
    Hauge EM, Mosekilde L, Melsen F, Frydenberg M 2001 How many patients are needed? Variation and design considerations in bone histomorphometry. Bone 28:556562.
  • 8
    Parfitt AM 1988 Bone histomorphometry: Proposed system for standardization of nomenclature, symbols, and units. Calcif Tissue Int 42:284286.
  • 9
    Ott SM 1993 Bone formation periods studied with triple tetracycline labels in women with postmenopausal osteoporosis. J Bone Miner Res 8:443450.
  • 10
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439446.
  • 11
    Bradbeer JN, Arlot ME, Meunier PJ, Reeve J 1992 Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 37:282289.
  • 12
    Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27:311318.
  • 13
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Müller R, Bilezikian JP, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:18461853.
  • 14
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:19321941.
  • 15
    Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:39703977.
  • 16
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962970.
  • 17
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745751.
    Direct Link:
  • 18
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:12161226.
  • 19
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:12071215.
  • 20
    Takahashi H, Hattner R, Epker BN, Frost HM 1964 Evidence that bone resorption precedes formation at the cellular level. Henry Ford Hosp Med Bull 12:359364.
  • 21
    Erben RG 1996 Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling? Anat Rec 246:3946.
  • 22
    Kobayashi S, Takahashi HE, Ito A, Saito N, Nawata M, Horiuchi H, Ohta H, Ito A, Iorio R, Yamamoto N, Takaoka K 2003 Trabecular minimodeling in human iliac bone. Bone 32:163169.
  • 23
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:11381148.
  • 24
    Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:36323638.
  • 25
    Parfitt AM 2002 Recent contributions of iliac bone histomorphometry to understanding the anabolic effect of parathyroid hormone IBMS BoneKEy 2002 Jan 29 doi: 10.1138/2002017.
  • 26
    Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP 1999 On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84:15621566.